Share Twitter LinkedIn Facebook Email Mark Fleming MD Of US Oncology Research Discusses Treatment Sequencing For Castrate Resistant M0 Disease: Looking At 3 Drugs Enzalutamide, Apalutamide, & Darolutamide, The Options Are The Challenge.
Overview of SYNC-T Technology from Syncromune in Prostate Cancer Treatment – Charles Link, MD Prostate 2 Mins Read
Pioneering Advances in Non-Metastatic Prostate Cancer: Navigating ARPIs and Precision Diagnostics for Tailored Treatment [39 SLIDES] Prostate 5 Mins Read
Promontory Therapeutics: PT-112 triggers organelle stress and ribosomal inhibition Prostate 2 Mins Read